Previous 10 | Next 10 |
LA JOLLA, CA / ACCESSWIRE / September 1, 2023 / Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but it is believed to involve a combination of ge...
La Jolla, California--(Newsfile Corp. - August 29, 2023) - GRI Bio, Inc. (NASDAQ: GRI), a clinical-stage biotechnology company developing novel immunotherapies that modulate natural killer T (NKT) cells, today announced it has engaged B2i Digital, Inc. ("B2i") to execute an innovative digital eng...
LA JOLLA, CA / ACCESSWIRE / August 25, 2023 / Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that are more widely known are Idiopathic Pulmonary Fi...
2023-08-24 10:00:34 ET Gainers: CollPlant Biotechnologies ( CLGN ) +11% NeuBase Therapeutics ( NBSE ) +7% NeuroPace ( NPCE ) +7% Bionomics ( BNOX ) +6% Enhabit ( EHAB ) +16% Losers: NanoVibronix ( NAOV ) -15% ...
2023-08-23 10:12:08 ET More on Healthcare sector XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air BofA experiences its thi...
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation technology for certain follow-on pipeline programs in development GRI to...
GRI Bio kicks-off the series by explaining what recently published preclinical data on its GRI-0803 Lupus development program means for its overall advancement FRENCHTOWN, NJ / ACCESSWIRE / August 16, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relatio...
Rapidly advancing c linical pipeline across multiple high-value i nflammatory, f ibrotic and a utoimmune d iseases On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before year end 2023 ...
Data p resented at The Autoimmunity Conference h osted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment of systemic lupus erythematosus (SLE) Company expects to com...
- Live moderated webcast fireside chat today, August 3 rd at 11 : 15 A M ET LA JOLLA, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology c...
News, Short Squeeze, Breakout and More Instantly...
Cohen & Steers Global Realty Majors Company Name:
GRI Stock Symbol:
NYSE Market:
Cohen & Steers Global Realty Majors Website:
Live video webcast on Wednesday, July 17 th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an inn...
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” ȁ...
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune dis...